POP BIO announces findings for an Alzheimer’s Disease polyvalent peptide immunotherapy
POP BIO announces findings for an Alzheimer’s Disease polyvalent peptide immunotherapy
POP BIO announces findings for an Alzheimer’s Disease polyvalent peptide immunotherapy
POP Biotechnologies announces the furtherance of research with FunPep. Advanced preclinical testing of antibody-inducing peptides will be carried out.
POP Biotechnologies announces the commencement of dosing of the shingles vaccine “EuHZV” in collaboration with EuBiologics in a Phase 1 clinical study in Korea
EuBiologics co.,Ltd has started Phase 1 testing of EuRSV, a next-generation RSV vaccine. This is now the second vaccine (after EuCorVac-19) to enter human testing based on POP Biotechnologies’ SNAP vaccine adjuvant system.
Abstract: .One of the strategies towards an effective HIV-1 vaccine is to elicit broadly neutralizing antibody responses that target the high HIV-1 Env diversity. Here, we present an HIV-1 vaccine candidate that consists of cobalt porphyrin-phospholipid (CoPoP) liposomes decorated with repaired and stabilized clade C HIV-1 Env trimers in a prefusion conformation. These particles exhibit high HIV-1 Env trimer decoration, serum stability and bind broadly neutralizing antibodies. Three sequential immunizations of female rabbits with CoPoP liposomes displaying a different clade C HIV-1 gp140 trimer at each dosing generate high HIV-1 Env-specific antibody responses. Additionally, serum neutralization is detectable against 18 of 20 multiclade tier 2 HIV-1 strains. Furthermore, the peak antibody titers induced by CoPoP liposomes can be recalled by subsequent heterologous immunization with Ad26-encoded membrane-bound stabilized Env antigens. Hence, a CoPoP liposome-based HIV-1 vaccine that can generate cross-clade neutralizing antibody immunity could potentially be a component of an efficacious HIV-1 vaccine.
POP Biotechnologies (POP BIO), a Buffalo, NY based biopharmaceutical startup, announces the approval of the plan for a phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics (KOSDAQ: 206650, CEO, Dr. Baik YoungOk, Mr. Seukkeun Choi) from the Ministry of Food and Drug Safety in South Korea. EuCorVac-19, is a protein-based vaccine consisting of Eubiologics protein antigen, EulMT, in-licensed from Korea Institute of Science and Technology and the spontaneous-nanoliposome antigen particle (SNAP) technology of POP BIO.